MedSIR will attend the Genitourinary Cancers Symposium (ASCO GU) for the second time in a row. The GU Symposium, now in its 15th year, will take place in San Francisco, CA from February 14 to 16, 2019. More than 4,500 attendants are expected at the Moscone Center, one of the largest convention and exhibition complexes in San Francisco. An array of multidisciplinary sessions covering prostate, renal, penile, testicular, urothelial and adrenal are to be featured.
From Breast Cancer to GU Tumors, via Digestive Tumors and Lung Cancer, MedSIR is on quite a ride since last year. This represents the organic (and fun) result of extrapolating its project acquisition and clinical trial management model from its core activity (breast cancer) to other tumor types.
While the goal of attending ASCO GU last year was to just get our feet wet, this time around MedSIR has a much clearer agenda including several key meetings regarding specific projects that we hope will translate into helping GU patients in the very near future. These projects span bladder, kidney, prostate and penile squamous cell carcinoma.
We are indeed very enthusiastic to be part of such an important symposium and look forward to meeting the individuals, institutions, and companies at the forefront of research in GU malignancies. These are the brilliant minds that are generating great ideas that could ultimately result in novel treatments that could benefit numerous patients worldwide – and MedSIR wants to be right there with them!
If you are a clinician, researcher or company in the GU domain and are looking for guidance for developing your research ideas, don’t miss out on the chance to meet with MedSIR these days at ASCO GU. Likewise, if you are a patient attending the conference and would like to get in touch, please do so – It would be our pleasure!
